Variant adeno-associated viruses and methods of use
The rAAV2-retro variant addresses the inefficiencies of existing viral vectors by enhancing retrograde transport to projection neurons, facilitating high-level transgene expression and genome editing, thereby improving neural circuit investigation and therapeutic interventions for neurodegenerative diseases.
Patent Information
- Application Number
- JP2022099286
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-10-05
- Filing Date
- 2022-06-21
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2037-06-15
AI Technical Summary
Existing viral vectors for delivering transgenes to projection neurons in the nervous system suffer from inefficient retrograde transport and limited clinical potential, hampering the investigation of neural circuits and therapeutic interventions for neurodegenerative diseases.
Engineering a variant adeno-associated virus (rAAV2-retro) with specific capsid protein sequences (xDxTKx and xDxTKxx) that enhance retrograde access to projection neurons, enabling high-level transgene expression and efficient genome editing.
rAAV2-retro achieves up to two orders of magnitude greater retrograde access to corticopontine projection neurons compared to CAV-2, allowing robust interrogation of neural circuits and effective gene therapy for neurodegenerative disorders.
Smart Images

Figure 0007579301000014 
Figure 0007579301000015 
Figure 0007579301000016
Abstract
Description
[Technical Field]
[0001] Federally sponsored research or development This invention was made with government support under EY022975 awarded by the National Institutes of Health (NIH). The government has certain rights in this invention.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. patent application Ser. No. 62 / 350,361, filed June 15, 2016, and U.S. patent application Ser. No. 62 / 404,585, filed October 5, 2016.
[0003] Technical Field The present disclosure relates generally to variant adeno-associated viruses and methods of making and using them. [Background technology]
[0004] background Brain functions such as perception, cognition, and motor control depend on the coordinated action of large-scale neuronal networks, composed of local circuit modules interconnected by long-range connections that perform specific computations and distribute the results of these computations. These long-range connections are often formed by specialized projection neurons, often consisting of several interwoven classes, each of which projects to various downstream targets within the network. Projection neurons are also implicated in the spread of several neurodegenerative diseases from their spatially localized sites of onset. Therefore, the ability to selectively target specific classes of projection neurons for transgene delivery (e.g., for activity monitoring / manipulation or genome editing for targeted gene knockout or repair of pathological mutations) is believed to be important both for gaining insight into how large-scale networks contribute to brain function and, in the long term, for therapeutic intervention in neurodegenerative diseases.
[0005] Viral vectors constitute an important class of tools for introducing transgenes into specific neuronal populations and are by far the best option for genetic access to target projection neurons through entry at axon terminals and retrograde transport of their payload to the cell nucleus. Numerous naturally evolved neurotropic viruses, including rabies, poliovirus, and herpes simplex virus (HSV), among others, exhibit retrograde propagation as part of their life cycle. Of these, rabies virus is particularly neuroinvasive, spreading rapidly through the nervous system by transcellular transfer. However, its potential for both biological research and gene therapy is hindered by excessive virulence, although progress has been made toward reducing its toxicity. In addition to naturally neurotropic strains, many other viruses can infect neurons when administered directly into the nervous system, with "pseudorabies" (SuHV1, actually a herpesvirus), adenovirus, and lentivirus being the most commonly used in animal research. Canine adenovirus-2 (CAV-2) exhibits the best infectivity and retrograde transport of any virus and is increasingly becoming the reagent of choice for accessing projection neurons. However, CAV-2 mediates only modest levels of transgene expression, exhibits potential for toxicity, and is not currently readily adaptable for scalable and reliable production for clinical-grade production or studies in larger animals. Therefore, there remains an urgent need for the development of nontoxic, easily manufactured viral vectors that allow flexible packaging of various transgenes, are reliably internalized and retrogradely transported by axons, and support long-term, high-level payload expression. Summary of the Invention
[0006] overview Efficient retrograde access to projection neurons for sensor and effector delivery constitutes a critical and enabling capability for circuit dissection. Such an approach would also be useful for gene therapy, including the treatment of neurodegenerative disorders characterized by pathological spread through functionally connected, highly distributed networks. Viral vectors are particularly powerful gene delivery vehicles for the nervous system, but all available tools suffer from inefficient retrograde transport or limited clinical potential. To address this need, we applied in vivo directed evolution to engineer potent retrograde functionality into the capsid of adeno-associated virus (AAV), a vector that has shown promise in neuroscience research and the clinic. The variant described herein, termed rAAV2-retro, allows reliable retrograde access to projection neurons with efficiency comparable to classical synthetic retrograde labeling reagents and enables high expression levels sufficient for functional circuit investigation and in vivo genome editing using CRISPR / Cas9 in targeted neuronal populations.
[0007] In one aspect, a viral capsid protein is provided comprising a sequence selected from the group consisting of xxDxTKx (SEQ ID NO: 1) and xDxTKxx (SEQ ID NO: 2). In one embodiment, the viral capsid protein has at least 95% sequence identity to SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, or 78. In one embodiment, the viral capsid protein has the sequence set forth in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, or 78. In one embodiment, the viral capsid protein is encoded by a nucleic acid having at least 95% sequence identity to SEQ ID NO: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, or 77. In one embodiment, the viral capsid protein is encoded by a nucleic acid having a sequence set forth in the sequence numbers of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77.
[0008] In yet another aspect, provided are viral particles comprising the viral capsid proteins described herein. In some embodiments, the viral particles exhibit a preference for retrograde transport. In some embodiments, the viral particles possess retrograde transport capability.
[0009] In some embodiments, the viral particle as described herein further comprises a nucleic acid encoding a payload. In some embodiments, the nucleic acid encoding the payload comprises a promoter sequence operably linked to the coding sequence encoding the payload. Representative promoter sequences include, but are not limited to, synapsin-1, CMV, GFAP, CAG, CaMKII, MBP, EF1α, TRE, and mDlx. In some embodiments, the coding sequence encoding the payload is selected from the group consisting of a protein-coding gene and an inhibitory RNA nucleic acid. In some embodiments, the inhibitory RNA nucleic acid is an antisense oligonucleotide, siRNA, or RNAi.
[0010] In some embodiments, the payload is effector protein.Representative effector protein includes but is not limited to recombinase (for example, Cre or Flp), gene editing system (for example, CRISPR / Cas9, TALEN, Zn-finger nuclease), optogenetic reagent (activator (for example, channelrhodopsin or its variant) or inhibitor (for example, halorhodopsin or Arch)), chemical genetic reagent (for example, the activator / inhibitor version of DREADD or PSAM / PSEM system), activator and / or inhibitor of cellular pathway and the enzyme for controlling epigenetics.
[0011] In some embodiments, the payload is an optical reporter construct. Representative optical reporter constructs include, but are not limited to, GCaMP6 (s, m, or f), fluorophores (e.g., green fluorescent protein (GFP), enhanced GFP (EGFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), tdTomato), color-flipping constructs (e.g., payloads that express one reporter in one cell population and a different reporter in another), glucose sensors, jRCaMP, jRGECO, and CaMPARI, voltage indicators, second messengers, receptor signaling substances, transcriptional reporters, epigenetic reporters, and neuromodulator reporters.
[0012] In some embodiments, the payload is a viral protein. A typical viral protein is rabies G protein. In some embodiments, the viral protein is a protein that complements the function of a virus other than AAV, or a protein that is involved in cellular transport and transcellular transport.
[0013] In some embodiments, the coding sequence encoding the payload is a therapeutic gene. In some embodiments, the therapeutic gene is for the treatment of a neurodegenerative disorder. In some embodiments, the therapeutic gene is HSP104 for the treatment of Alzheimer's disease or other diseases with toxic protein aggregates. In some embodiments, the therapeutic gene is frataxin for the treatment of Friedreich's ataxia. In some embodiments, the therapeutic gene is lysosomal glucocerebrosidase (GBA) for the treatment of Parkinson's disease. In some embodiments, the therapeutic gene is polyQ-binding protein for the treatment of Huntington's disease. In some embodiments, the therapeutic gene is survival motor neuron 1 for the treatment of spinal muscular atrophy, amyotrophic lateral sclerosis (ALS), autism, dementia, peripheral neuropathy, schizophrenia, or retinal degeneration.
[0014] In some embodiments, the payload is a therapeutic moiety. An exemplary therapeutic moiety is an antibody or fragment thereof. An exemplary therapeutic moiety is an immunomodulatory protein. An exemplary therapeutic moiety is an RNA interference molecule.
[0015] In some embodiments, the viral particles described herein exhibit retrograde access to cortico-pontine projection neurons that is up to two orders of magnitude greater than canine adenovirus-2 (CAV-2). In some embodiments, retrograde access to cortico-pontine projection neurons or afferents to the dorsomedial striatum (DMS) is comparable to the synthetic tracer Fluoro-Gold fluorescent beads.
[0016] In another aspect, a method for delivering a payload to one or more neurons is provided. Such a method typically includes contacting one or more neurons with a variant adeno-associated virus (AAV) containing a payload packaged therein, wherein the variant AAV comprises a capsid protein comprising a sequence selected from the group consisting of xxDxTKx (SEQ ID NO: 1) and xDxTKxx (SEQ ID NO: 2). In some embodiments, the variant AAV exhibits retrograde transport in neurons.
[0017] In some embodiments, the neuron is a projection neuron. In some embodiments, the neuron is in a subject (e.g., in the central nervous system (CNS) of a subject). In some embodiments, the subject is a human. In some embodiments, the subject is a non-human (e.g., a primate, rodent, reptile, or avian). In some embodiments, the contacting step is performed in cell culture. In some embodiments, the contacting step is in vivo via intracranial, intraspinal, or intramuscular injection.
[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the relevant method and composition belongs.Methods and materials similar to or equivalent to those described herein can be used in carrying out or testing the method and composition in question, and suitable methods and materials are described below.In addition, materials, methods and examples are only illustrative and are not intended to be limiting.All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. [The present invention 1001] A viral capsid protein comprising a sequence selected from the group consisting of xxDxTKx (SEQ ID NO: 1) and xDxTKxx (SEQ ID NO: 2). [The present invention 1002] 1001. A viral capsid protein of the present invention having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78. [The present invention 1003] 1001. A viral capsid protein of the present invention having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78. [The present invention 1004] 1001. A viral capsid protein of the present invention encoded by a nucleic acid having at least 95% sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77. [The present invention 1005] 1001. A viral capsid protein of the present invention encoded by a nucleic acid having a sequence selected from the group consisting of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77. [The present invention 1006] A virus particle comprising any one of the viral capsid proteins of the present inventions 1001 to 1005. [The present invention 1007] 1006. A viral particle of the present invention that exhibits a preference for retrograde movement. [The present invention 1008] 1006. A viral particle of the present invention that possesses retrograde transport ability. [The present invention 1009] The viral particle of any one of 1006 to 1008, further comprising a nucleic acid encoding a payload. [The present invention 1010] 1009. The viral particle of claim 10, wherein the nucleic acid encoding the payload comprises a promoter sequence operably linked to a coding sequence encoding the payload. [The present invention 1011] 10. The viral particle of the present invention, wherein the promoter is selected from the group consisting of synapsin-1, CMV, GFAP, CAG, CaMKII, MBP, EF1α, TRE, and mDlx. [The present invention 1012] The viral particle of the present invention 1010 or 1011, wherein the coding sequence encoding the payload is selected from the group consisting of a protein-encoding gene and an inhibitory RNA nucleic acid. [The present invention 1013] The viral particle of the present invention, wherein the inhibitory RNA nucleic acid is an antisense oligonucleotide, an siRNA, or an RNAi. [The present invention 1014] 1009. The viral particle of the present invention, wherein the payload is an effector protein. [The present invention 1015] The viral particle of the present invention, wherein the effector protein is selected from the group consisting of a recombinase (e.g., Cre or Flp), a gene editing system (e.g., CRISPR / Cas9, TALEN, Zn-finger nuclease), an optogenetic reagent (an activator (e.g., channelrhodopsin or a variant thereof) or an inhibitor (e.g., halorhodopsin or Arch)), a chemogenetic reagent (e.g., an activator / inhibitor version of a DREADD or PSAM / PSEM system), an activator and / or inhibitor of a cellular pathway, and an enzyme for controlling epigenetics. [The present invention 1016] 1009. A viral particle of the present invention, wherein the payload is an optical reporter construct. [The present invention 1017] The viral particle of the present invention, wherein the optical reporter construct is selected from the group consisting of GCaMP6 (s, m, or f), a fluorophore (e.g., green fluorescent protein (GFP), enhanced GFP (EGFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), tdTomato), a color-flipping construct (e.g., a payload that expresses one reporter in one cell population and a different reporter in another population), a glucose sensor, jRCaMP, jRGECO, and CaMPARI, a voltage indicator, a second messenger, a receptor signaling agent, a transcriptional reporter, an epigenetic reporter, and a neuromodulator reporter. [The present invention 1018] 1009. A viral particle according to the present invention, wherein the payload is a viral protein. [The present invention 1019] 1018. The virus particle of the present invention, wherein the viral protein is rabies G protein. [The present invention 1020] The viral particle of the present invention, wherein the viral protein is a protein that complements the function of a virus other than AAV, or is a protein involved in cellular transport and transcellular transport. [The present invention 1021] 1009. The viral particle of the present invention, wherein the coding sequence encoding the payload is a therapeutic gene. [The present invention 1022] The viral particle of the present invention 1021, wherein the therapeutic gene is for the treatment of a neurodegenerative disorder. [The present invention 1023] 1022. The viral particle of the present invention, wherein the therapeutic gene is HSP104 for the treatment of Alzheimer's disease or other diseases with toxic protein aggregates. [The present invention 1024] The viral particle of the present invention 1022, wherein the therapeutic gene is frataxin for the treatment of Friedreich's ataxia. [The present invention 1025] 1022. The viral particle of the present invention, wherein the therapeutic gene is lysosomal glucocerebrosidase (GBA) for the treatment of Parkinson's disease. [The present invention 1026] 1022. The viral particle of the present invention, wherein the therapeutic gene is a polyQ binding protein for the treatment of Huntington's disease. [The present invention 1027] The viral particle of the present invention 1022, wherein the therapeutic gene is survival motor neuron 1 for the treatment of spinal muscular atrophy, amyotrophic lateral sclerosis (ALS), autism, dementia, peripheral neuropathy, schizophrenia, or retinal degeneration. [The present invention 1028] The viral particle of the present invention 1009, wherein the payload is a therapeutic moiety. [The present invention 1029] The viral particle of the present invention 1028, wherein said therapeutic moiety is an antibody or a fragment thereof. [The present invention 1030] 1028. The viral particle of claim 1028, wherein said therapeutic moiety is an immunomodulatory protein. [The present invention 1031] 1028. The viral particle of claim 1028, wherein said therapeutic moiety is an RNA interference molecule. [The present invention 1032] 10. The viral particle of any of claims 1006 to 1028, which exhibits retrograde access to cortico-pontine projection neurons up to two orders of magnitude larger than canine adenovirus-2 (CAV-2). [The present invention 1033] The viral particle of any of claims 1006 to 1028, wherein retrograde access to corticopontine projection neurons or afferents to the dorsomedial striatum (DMS) is comparable to the synthetic tracer Fluoro-Gold fluorescent beads. [The present invention 1034] contacting one or more neurons with a variant adeno-associated virus (AAV) comprising a packaged payload, wherein the variant AAV comprises a capsid protein comprising a sequence selected from the group consisting of xxDxTKx (SEQ ID NO:1) and xDxTKxx (SEQ ID NO:2); A method for delivering a payload to one or more neurons, comprising: [This invention 1035] The method of claim 1034, wherein the variant AAV exhibits retrograde migration in neurons. [The present invention 1036] The method of claim 1034, wherein the neuron is a projection neuron. [This invention 1037] 1036. The method of any one of claims 1034 to 1036, wherein the neuron is in a subject. [The present invention 1038] The method of any of claims 1034 to 1037, wherein said neuron is in the central nervous system (CNS) in a subject. [This invention 1039] The method of any one of claims 1034 to 1038, wherein the subject is a human. [The present invention 1040] The method of any one of claims 1034 to 1038, wherein the subject is a non-human. [This invention 1041] The method of claim 1040, wherein said non-human subject is a primate, rodent, reptile, or avian. [The present invention 1042] 1037. The method of any one of claims 1034 to 1036, wherein the contacting step is carried out in a cell culture. [This invention 1043] 1042. The method of any one of claims 1034 to 1041, wherein said contacting step is carried out in vivo via intracranial injection, intraspinal injection, or intramuscular injection. [Brief explanation of the drawings]
[0019] [Figure 1A] Directed evolution of rAAV2-retro is shown. Panel A of Figure 1 shows a schematic diagram of the directed evolution procedure. A plasmid library containing variant AAV cap genes previously generated by error-prone PCR, peptide insertion, loop region randomization, and DNA shuffling was packaged and injected into the substantia nigra or deep cerebellar nuclei. Three weeks later, striatal or hindbrain tissue, respectively, was removed, viral genomes were isolated, and selected cap genes were amplified and packaged for the next round of selection. Panel B of Figure 1 shows mixed subpopulations of cortical neurons projecting to the striatum (caudate-putamen), thalamus, and superior colliculus (SC), which were retrogradely labeled by injecting rAAV2-retro carrying various fluorescent proteins in the corresponding axonal fields. [Figure 1B] See legend to Figure 1A. [Figure 2A]Results from an experiment quantifying retrograde transport efficiency are shown. Panel A of Figure 2 shows the corticopontine tract labeled via basal pontine injection of rAAV2-retro (the upper panel of Panel A shows a schematic of the experiment; targeting consistency and injection quality were monitored by co-injection of AAV1-CAG-EGFP. The lower panel of Panel A shows the expression level 3 weeks after injection. Scale bar: 1 mm). Panel B of Figure 2 shows the design of the quantification assay (the upper panel of Panel B shows a schematic of the experiment; arrows indicate expected nuclear GFP labeling in cortical neurons in the corticopontine tract. The middle panel of Panel B shows a representative image of an AAV2-injected brain. The lower panel of Panel B shows a representative image of an rAAV2-retro-injected brain. Scale bar: 1 mm). Panel C of Figure 2 shows a schematic of the semi-automated quantification procedure. Nuclei of fluorescence (green) were automatically detected and counted along manually drawn lines (black) that traced the length of the cortical layer V. Panel D of Figure 2 shows the retrograde transport efficiency for various AAV serotypes and for canine adenovirus-2 (CAV-2). Error bars represent SEM. See also Figure 8. [Figure 2B] See legend to Figure 2A. [Figure 2C] See legend to Figure 2A. [Figure 2D] See legend to Figure 2A. [Figure 3A]Results from an experiment demonstrating the generality of retrograde transport mediated by rAAV2-retro are shown. Panel A of Figure 3 shows representative images demonstrating widespread labeling in major input structures to the dorsal striatum, including the cortex (image number 1), amygdala (image number 3), and thalamus (image number 4). Panel B of Figure 3 shows a schematic diagram of automated whole-brain quantification of retrograde labeling. A Rosa26-LSL-H2B-GFP brain injected with rAAV2-retro hSyn1-Cre was imaged to visualize DAPI-stained nuclei and green fluorescence from H2B-GFP-expressing nuclei. The green channel was used to detect labeled neurons; the blue channel was aligned to a Nissl image from a standard mouse brain at the Allen Brain Institute. Using annotations provided by this brain atlas, alignment allowed the assignment of detected neurons to various regions. Scale bar: 1.25 mm. Panel C of Figure 3 shows whole-brain quantification of retrograde labeling out of a small region of the dorsomedial striatum. Abbreviations for various brain regions are shown according to the Allen Brain Atlas. The arrow highlights the SNc. Error bars represent SEM. [Figure 3B] See legend to Figure 3A. [Figure 3C] See legend to Figure 3C. [Figure 4] Data from an experiment combining the rAAV2-retro system with a Cre driver line. Panel A of Figure 4 shows a schematic of the experiment. rAAV2-retro carrying a Cre-dependent color-flipping fluorescent reporter was injected into the striatum of a cortical V-specific Cre line. Panel B of Figure 4 shows two corticostriatal pathways, one differentially labeled through Cre-dependent flipping of the reporter, but the other unlabeled. [Figure 5A]Data from an experiment demonstrating that rAAV2-retro supports transgene expression sufficient for the investigation of functional circuits. Panel A of Figure 5 shows a schematic of the experiment. Expression of the calcium indicator GCaMP6f was restricted to corticopontine neurons using localized injection of rAAV2-retro into the basal pons. Panel B of Figure 5 is a transverse section of the brain showing GCaMP6f expression throughout the corticopontine tract. Panel C of Figure 5 shows a maximal projection of two-photon calcium images showing layer V pyramidal tract cell bodies and apical dendrites. Panel D of Figure 5 shows activity in 89 ROIs during a single hand reach repetition (dashed lines indicate a tone "go" signal). Panels E and F of Figure 5 are two examples of a single corticopontine neuron during 40 consecutive trials (same animal as Panels B and D of Figure 5). [Figure 5B] See legend to Figure 5A. [Figure 5C] See legend to Figure 5A. [Figure 5D] See legend to Figure 5A. [Figure 5E] See legend to Figure 5A. [Figure 5F] See legend to Figure 5A. [Figure 6A]These data demonstrate that the rAAV2-retro system enables in vivo genome editing using CRISPR / Cas9. Panel A of Figure 6 shows a schematic of the experiment. [The top panel of Panel A shows the rAAV2-retro system being used to deliver a Staphylococcus aureus Cas9 (SaCas9)-single guide RNA combination engineered to eliminate tdTomato expression. The bottom panel of Panel A shows the injection of rAAV2-retro carrying a SaCas9-anti-tdTomato payload into the basal pons of mice expressing tdTomato from a single genomic locus in layer V neurons.] Panel B of Figure 6 shows representative images from brain sections of animals that received the CRISPR / Cas9 system either targeted against tdTomato or carrying a non-targeting guide. SaCas9 is epitope-tagged, allowing for the identification of retrogradely labeled neurons (green channel). The upward arrow indicates the expected labeling after successful removal of tdTomato; the downward arrow indicates the expected labeling when tdTomato expression is unaffected. Panel C of Figure 6 shows the efficiency of removal. Error bars represent SEM. [Figure 6B] See legend to Figure 6A. [Figure 6C] See legend to Figure 6A. [Figure 7A] These data demonstrate that rAAV2-retro mediates efficient access to projection neurons in rats (data shown in Figure 7 are related to those shown in Figure 1). Panel A of Figure 7 shows a schematic of the injections. Separate lots of rAAV2-retro expressing EGFP or tdTomato were injected into the striatum or superior colliculus, respectively. Panels B–E of Figure 7 show projection neurons in various brain regions accessed through these localized injections and imaged 3 weeks after viral delivery. [Figure 7B] See legend to Figure 7A. [Figure 7C] See legend to Figure 7A. [Figure 7D]See legend to Figure 7A. [Figure 7E] See legend to Figure 7A. [Figure 8] Representative images of brains from animals injected with various AAV serotypes in the basal pons, showing that non-naturally occurring AAV serotypes match the performance of rAAV2-retro in corticopontine circuits (data shown in Figure 8 are related to data shown in Figure 2). [Figure 9] Figure 9 shows data demonstrating reduced heparin affinity for rAAV2-retro compared to its parent serotype, AAV2 (data shown in Figure 9 are related to data shown in Figure 1). Panel A of Figure 9 is a schematic of the heparin binding assay. Panel B of Figure 9 shows the fractions of virus eluted with increasing concentrations of NaCl after loading at 150 mM NaCl. The load fraction represents the virus recovered in the column flow-through after sample loading at 150 mM NaCl. Error bars represent SD. DETAILED DESCRIPTION OF THE INVENTION
[0020] Detailed Description Recombinant adeno-associated viruses (rAAVs) have emerged as an effective platform for in vivo gene therapy because they mediate high levels of transgene expression, are nontoxic, and elicit minimal immune responses. These properties were at the heart of the decision to grant the first full regulatory approval of any gene therapy treatment to rAAV-mediated reversal of lipoprotein lipase deficiency (see, e.g., Gaudet et al., 2010, Atherosclerosis Supplem., 11:55-60). rAAVs have shown great promise in clinical trials for a range of neurological disorders and constitute some of the most widely used vectors in neuroscience research. Since the initial discovery that AAV can undergo retrograde transport (Kaspar et al., 2002, Mol. Ther., 5:50-56), rAAV has some retrograde access to projection neurons in select circuits, but its natural propensity for retrograde transport is low, hindering efforts to address the role of projection neurons in circuit computation or disease progression.
[0021] This disclosure describes a new rAAV variant (rAAV2-retro) that, in addition to its conventional ability to infect neuronal cell bodies at the site of exposure, is reliably internalized by axons and mediates retrograde access to projection neurons with efficiency comparable to classical retrograde labeling reagents such as synthetic dyes. The rAAV2-retro gene delivery system described herein can be used by itself or in conjunction with a Cre recombinase driver line to achieve long-term, high-level transgene expression sufficient for effective functional investigation of neural circuit function and genome editing in targeted neuronal populations.
[0022] Retrograde transport shuttles molecules and / or organelles away from the axon terminal toward the cell body. Retrograde axonal transport is mediated by cytoplasmic dynein and is used, for example, to transport chemical messages and endocytic products destined for endolysosomes back from the axon to the cell. Fast retrograde transport operates in vivo at an average speed of approximately 2 μm / s and can cover 10-20 centimeters per day. Fast retrograde transport returns used synaptic vesicles and other materials to the cell body, informing the cell body of the status at the axon terminal. Therefore, as used herein, "retrograde" transport refers to movement in the axon toward its cell body.
[0023] Adeno-associated virus (AAV) nucleic acid and polypeptide sequences As described herein, consensus sequences have been identified that, when present in AAV capsid proteins, result in a significant increase in the efficacy of retrograde transport. These consensus sequences are xxDxTKx (SEQ ID NO: 1) or xDxTKxx (SEQ ID NO: 2). To demonstrate the effectiveness of the consensus sequences described herein for conferring retrograde transport ability, 17 different capsid sequences, each containing the consensus sequence described herein, were generated and shown to exhibit a preference for retrograde transport in neurons. The nucleic acid sequences of these 40 capsid sequences are set forth in SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77, respectively, and the encoded capsid polypeptides, each containing one of the consensus sequences described herein, are set forth in SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78.
[0024] In addition to the capsid polypeptides having the sequences set forth in SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78, Polypeptides having at least 95% sequence identity (e.g., at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) to capsid polypeptides having the sequences set forth in SEQ ID NOs: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, and 78 are provided. Similarly, in addition to the nucleic acid molecules having the sequences set forth in SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77, Nucleic acid molecules having at least 95% sequence identity (e.g., at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity) to nucleic acid molecules having the sequences set forth in SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, and 77 are provided.
[0025] In calculating percent sequence identity, two sequences are aligned and the number of perfect matches of nucleotides or amino acid residues between the two sequences is determined. The number of perfect matches is divided by the length of the aligned region (i.e., the number of aligned nucleotides or amino acid residues) and multiplied by 100 to arrive at a percent sequence identity value. It will be recognized that the length of the aligned region can be a portion of one or both sequences, up to the full-length size of the shortest sequence. It will also be recognized that a single sequence can be aligned with more than one other sequence and therefore can have different percent sequence identity values across each aligned region.
[0026] Alignment of two or more sequences to determine percent sequence identity can be performed using the algorithm described by Altschul et al. (1997, Nucleic Acids Res., 25:3389-3402), as incorporated into the BLAST (basic local alignment search tool) program, available on the World Wide Web at ncbi.nlm.nih.gov. BLAST searches can be performed using the Altschul et al. algorithm to determine the percent sequence identity between a sequence (nucleic acid or amino acid) and any other aligned sequence or portion thereof. BLASTN is a program used to align nucleic acid sequences and compare the identity therebetween, while BLASTP is a program used to align amino acid sequences and compare the identity therebetween. When using BLAST programs to calculate the percent identity between a sequence and another sequence, the default parameters of the respective programs are generally used.
[0027] Vectors containing nucleic acid molecules encoding polypeptides are also provided. Vectors, including expression vectors, are commercially available or can be produced by recombinant technology. Vectors containing nucleic acid molecules can have one or more elements for expression operably linked to such nucleic acid molecules and can further include sequences such as those encoding selectable markers (e.g., antibiotic resistance genes) and / or those that can be used in purifying the polypeptide (e.g., a 6xHis tag). Elements for expression include nucleic acid sequences that direct and regulate the expression of nucleic acid coding sequences. One example of an expression element is a promoter sequence. Expression elements can also include one or more introns, enhancer sequences, response elements, or inducible elements that regulate the expression of the nucleic acid molecule. Expression elements can be of bacterial, yeast, insect, mammalian, or viral origin, and vectors can contain a combination of expression elements from various sources. As used herein, operably linked means that the elements for expression are located in the vector relative to the coding sequence so as to direct or regulate the expression of the coding sequence.
[0028] Nucleic acid molecules, e.g., nucleic acid molecules in a vector (e.g., expression vector, viral vector), can be introduced into a host cell. The term "host cell" refers not only to the particular cell into which a nucleic acid molecule has been introduced, but also to the progeny or potential progeny of such a cell. Many suitable host cells are known to those of skill in the art; host cells can be prokaryotic (e.g., E. coli) or eukaryotic (e.g., yeast, insect, plant, or mammalian) cells. Exemplary host cells include, but are not limited to, A549, WEHI, 3T3, 10T1 / 2, BHK, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, VERO, WI38, HeLa, 293 cells, Saos, C2C12, L cells, HT1080, HepG2, and primary fibroblasts, hepatocytes, and myoblasts from mammals, including humans, monkeys, mice, rats, rabbits, and hamsters. Methods for introducing nucleic acid molecules into host cells are well known in the art and include, but are not limited to, calcium phosphate precipitation, electroporation, heat shock, lipofection, microinjection, and viral-mediated nucleic acid transfer (e.g., transduction).
[0029] With respect to polypeptides, "purified" refers to a polypeptide (i.e., a peptide or polypeptide) that has been separated or purified from cellular components that naturally accompany it. Typically, a polypeptide is considered "purified" when it is at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, or 99%) by dry weight free from polypeptides and naturally occurring molecules with which it is naturally associated. Chemically synthesized polypeptides are considered "purified" because they are, by nature, separated from components that naturally accompany them, but synthetic polypeptides can further be removed from components (e.g., amino acid residues) used to synthesize the polypeptide. With respect to nucleic acid molecules, "isolated" refers to a nucleic acid molecule that is separated from other nucleic acid molecules that are normally associated with it in the genome. In addition, isolated nucleic acid molecules can include nucleic acid molecules that have been produced through manipulation, such as recombinant or synthetic nucleic acid molecules.
[0030] Polypeptides can be obtained (e.g., purified) from natural sources (e.g., biological samples) by known methods such as DEAE ion exchange, gel filtration, and / or hydroxyapatite chromatography. Purified polypeptides can also be obtained, for example, by expressing nucleic acid molecules in expression vectors or by chemical synthesis. The degree of purity of a polypeptide can be measured using any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. Similarly, nucleic acid molecules can be obtained (e.g., isolated) using routine methods, including, but not limited to, recombinant nucleic acid technology (e.g., restriction enzyme digestion and ligation) or polymerase chain reaction (PCR; see, e.g., PCR Primer: A Laboratory Manual, Dieffenbach & Dveksler, Eds., Cold Spring Harbor Laboratory Press, 1995). In addition, isolated nucleic acid molecules can be chemically synthesized.
[0031] Methods for producing viral particles that exhibit a preference for retrograde movement in neurons Once the capsid polypeptide is produced, or once the nucleic acid molecule is generated and expressed to produce the capsid polypeptide, the polypeptide can be assembled into a viral particle, for example, using a packaging host cell. The components of the viral particle (e.g., rep sequence, cap sequence, inverted terminal repeat (ITR) sequence) can be transiently or stably introduced into the packaging host cell using one or more vectors. The capsid polypeptide of the viral particle can contain a consensus sequence as described herein, while the remaining components can be derived from one or more known AAV serotypes (e.g., AAV2, AAV8, etc.).
[0032] Such viral particles can be purified using routine methods. As used herein, "purified" viral particles refer to viral particles that have been removed from components in the mixture in which they are produced, such as, but not limited to, viral components (e.g., rep sequences, cap sequences), packaging host cells, and partially or incompletely assembled viral particles.
[0033] Once assembled, viral particles can be screened for, for example, the ability to replicate; gene transfer properties; receptor binding ability; and / or seroprevalence in a population (e.g., a human population).Determining whether a viral particle can replicate is routine in the art, and typically involves infecting a host cell with a certain amount of viral particles and determining whether the number of viral particles increases over time.Determining whether a viral particle can perform gene transfer is also routine in the art, and typically involves infecting a host cell with viral particles containing a transgene (e.g., a detectable transgene, such as a reporter gene).After virus infection and elimination, the host cell can be evaluated for the presence or absence of the transgene.Determining whether a viral particle binds to its receptor is routine in the art, and such a method can be performed in vitro or in vivo.
[0034] Determining the seroprevalence of viral particles is routinely performed in the art and typically involves using immunoassays to determine the prevalence of one or more antibodies in samples (e.g., blood samples) from a particular population of individuals. Seroprevalence is understood in the art to refer to the proportion of subjects in a population who are seropositive (i.e., have been exposed to a particular pathogen or immunogen) and is calculated as the number of subjects in the population who produce antibodies to a particular pathogen or immunogen divided by the total number of individuals in the population under consideration. Immunoassays are well known in the art and include, but are not limited to, immunoblots, Western blots, enzyme immunoassays (EIAs), enzyme-linked immunosorbent assays (ELISAs), or radioimmunoassays (RIAs). Similarly, several methods are available for determining the level of neutralizing antibodies in serum samples. For example, a neutralizing antibody assay measures the titer at which an experimental sample contains an antibody concentration that neutralizes infection by 50% or more when compared to a control sample without antibodies. See also Fisher et al. (1997, Nature Med., 3:306-12) and Manning et al. (1998, Human Gene Ther., 9:477-85).
[0035] Methods using viruses that exhibit a preference for retrograde migration in neurons Viruses or portions thereof as described herein can be used in numerous research and / or therapeutic applications.For example, viruses or portions thereof as described herein can be used in human or animal medicine for gene therapy (e.g., in vectors or vector systems for gene transfer) or vaccination (e.g., for antigen presentation).More specifically, viruses or portions thereof as described herein can be used for gene addition, gene enhancement, genetic delivery of polypeptide therapeutics, genetic vaccination, gene silencing, genome editing, gene therapy, RNAi delivery, cDNA delivery, mRNA delivery, miRNA delivery, miRNA sponging, genetic immunization, optogenetic gene therapy, genetic recombination, DNA vaccination, or DNA immunization.
[0036] Host cells can be transduced or infected with a virus or a portion thereof in vitro (e.g., grown in culture) or in vivo (e.g., in a subject, e.g., a human or non-human). Host cells that can be transduced or infected with a virus or a portion thereof in vitro are described herein; host cells that can be transduced or infected with a virus or a portion thereof in vivo include, but are not limited to, projection neurons (e.g., corticopontine projection neurons, sympathetic projection neurons, central nervous system projection neurons), afferents to the dorsomedial striatum (DMS), spinal cortical / fungal neurons, pre-cerebellar neurons, inputs to the basal ganglia, pre-thalamic neurons, motor neurons, sensory neurons, or other neurons or cells of the central nervous system.
[0037] A virus or a portion thereof as described herein can be modified to include a payload. The payload typically includes at least one type of nucleic acid (e.g., a promoter sequence operably linked to a coding sequence encoding the payload). In certain instances, the payload can be an inhibitory nucleic acid. Inhibitory nucleic acids are known in the art and include, for example, antisense oligonucleotides, short interfering RNAs (siRNAs), and RNA interference (RNAi) molecules. In certain instances, the payload can be one or more protein-encoding genes. Without limitation, protein-encoding genes include optical reporter constructs, therapeutic genes, or effector proteins.
[0038] Many types of optical reporter constructs are known in the art, and the following list is meant to be representative and not exhaustive. For example, optical reporter constructs include, but are not limited to, GCaMP6 (GCaMP6s, GCaMP6m, or GCaMP6f; see WO 2014 / 059154), fluorophores (e.g., green fluorescent protein (GFP), enhanced GFP (EGFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), tdTomato), color-flipping constructs (e.g., expressing one reporter in one cell population and one reporter in another), and color-flipping constructs (e.g., expressing one reporter in one cell population and one reporter in another). payloads expressing different reporters at different sites), glucose sensors (e.g., U.S. Patent Application Publication No. 2015 / 0111222), iRCaMP (U.S. Patent No. 9,644,007), iRGECO (e.g., U.S. Patent No. 9,644,007), CaMPARI (e.g., U.S. Patent No. 9,518,996), voltage indicators, second messengers, receptor signaling substances, transcriptional reporters, epigenetic reporters, and neuromodulator reporters.
[0039] Therapeutic genes are also known in the art and will depend on the specific disease or disorder being treated. For example, the therapeutic gene can be for the treatment of neurodegenerative disorders. Representative therapeutic genes (or encoded polypeptides) and their associated neurodegenerative disorders include, but are not limited to, HSP104 for the treatment of Alzheimer's disease, Ataxis (e.g., frataxin) for the treatment of Friedreich's ataxia, lysosomal glucocerebrosidase (GBA) for the treatment of Parkinson's disease, polyQ-binding protein for the treatment of Huntington's disease, survival motor neuron 1 for the treatment of spinal muscular atrophy and amyotrophic lateral sclerosis (ALS), autism, dementia, peripheral neuropathy, schizophrenia, and retinal degeneration. In some examples, the payload (different from the gene) may be a therapeutic moiety. Therapeutic moieties include, for example, antibodies or fragments thereof, immunomodulatory proteins, or RNA interference (RNAi) molecules.
[0040] As used herein, "effector" protein refers to any type of protein that exerts an effect on a cell or its contents (e.g., nucleic acid, protein, organelle, or process involving any of the above). For example, effector proteins include, but are not limited to, recombinases (e.g., Cre or Flp), gene editing systems (e.g., CRISPR / Cas9, TALEN, Zn-finger nuclease), optogenetic reagents (activators (e.g., channelrhodopsin or its variants) or inhibitors (e.g., halorhodopsin or Arch)), chemical genetic reagents (e.g., activator / inhibitor versions of DREADD or PSAM / PSEM systems), activators and / or inhibitors of cellular pathways, and enzymes for controlling epigenetics.
[0041] It will be appreciated that it may be desirable to deliver a viral protein that complements or inhibits the function of a virus (e.g., a virus other than AAV), for example, an entry receptor (e.g., rabies G protein, a protein involved in cellular trafficking and / or transcytosis).
[0042] Any number of promoters can be used to drive the sequence encoding payload.Constitutive promoters are known in the art, as well as tissue-specific promoters (for example, neuron-specific promoters).Simply by way of example, promoters can be synapsin-1, CMV, GFAP, CAG, CaMKII, MBP, EF1α, mDlx or TRE promoters.
[0043] Typically, a virus or a portion thereof suspended in a physiologically compatible carrier can be administered to a subject (e.g., a human or non-human subject (e.g., a primate, rodent, reptile, or bird)). Suitable carriers include saline (e.g., phosphate-buffered saline), which can be formulated with various buffer solutions (e.g., phosphate-buffered saline), lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, and water. The virus or a portion thereof is administered in an amount sufficient to transduce or infect cells and to provide sufficient levels of gene transfer and expression to provide therapeutic benefit without undue adverse effects. Conventional and pharmaceutically acceptable routes of administration include, but are not limited to, intracranial, intraspinal, or intramuscular injection. Additional routes of administration include, for example, oral, intranasal, intratracheal, inhalation, intravenous, intraocular, subcutaneous, intradermal, transmucosal, or other routes of administration. Routes of administration can be combined, if desired.
[0044] The dose of the virus or portion thereof administered to a subject will depend primarily on factors such as the condition being treated and the age, weight, and health of the subject. For example, a therapeutically effective dosage of a virus or portion thereof to be administered to a human subject will generally be about 1 x 10 1~1×10 12 genome copies (GC) of virus (e.g., approximately 1 × 10 3 ~1×10 9 The concentration of the transgene in the solution ranges from about 0.1 ml to about 10 ml, containing a concentration of GC. Transduction and / or expression of the transgene can be monitored at various times after administration by DNA, RNA, or protein assays. In some instances, the level of transgene expression can be monitored to determine the frequency and / or amount of dosing.
[0045] Significantly, the AAV-retro particles described herein exhibit retrograde access to corticopontine projection neurons that is up to two orders of magnitude greater than, for example, canine adenovirus-2 (CAV-2), and retrograde access to certain neurons (e.g., corticopontine projection neurons, or afferents to the dorsomedial striatum (DMS)) is comparable to that observed with synthetic tracers such as Fluoro-Gold® fluorescent beads.
[0046] According to the present invention, conventional molecular biology, microbiology, biochemistry and recombinant DNA methods within the skill of the art can be used.Such techniques are fully explained in the literature.The present invention will be further described in the following examples, which do not limit the scope of the subject methods and compositions described in the appended claims. [Example]
[0047] Example 1 - Experimental Procedure All procedures were performed in accordance with protocols approved by the Janelia Research Campus and University of California, Berkeley Institutional Animal Care and Use Committees.
[0048] Example 2 - Library generation and virus production Four previously generated viral vectors were used at the start of the directed evolution procedure: 1) a random mutagenesis library generated by subjecting the AAV2 cap gene (encoding viral proteins VP1-3 and assembly activating protein (AAP)) to error-prone PCR (Maheshri et al., 2006, Nat. Biotechnol., 24:198-204); 2) a library of AAV2 cap gene variants containing a 7-mer peptide insert between N587 and R588 (Muller et al., 2003, Nat. Biotechnol., 21:1040-6); 3) a library of AAV2 cap gene variants containing randomized loop regions (Koerber et al., 2009, Mol. Ther., 17:2088-95); and 4) wild-type AAV1, AAV2, AAV4, AAV5, AAV6, AAV8, and AAV9. A DNA shuffling library was generated from cap gene sequences (Koerber et al., 2008, Mol. Ther., 16:1703-9). Each pool of mutant DNA was originally subcloned into a replication-competent AAV packaging plasmid to create a viral plasmid library that, when packaged into AAV virions, could be selected for any new properties or functions. The replication-competent AAV system incorporates mutant cap genes into the viral payload, thus linking the genotype of each variant to its phenotype. Capsid sequences with desired properties can then be recovered by DNA sequence analysis of the enveloped AAV genome.
[0049] Four replication-competent AAV libraries were packaged by calcium phosphate transient transfection of HEK293-T cells, followed by virus harvest, iodixanol gradient centrifugation, and Amicon filtration (Maheshri et al., 2006, Nat. Biotechnol., 24:198-204).
[0050] Example 3 - In vivo virus or tracer injection For localized in vivo virus delivery, mice or rats were anesthetized with isoflurane (approximately 2% by volume in O; SurgiVet, Smiths Medical), and a small hole was drilled in the skull above the desired injection site (see Table 1). For several injection sites, several injections were performed at different depths (see Table 1). For virus injections, approximately 50–100 nl (mice) or 250–500 nl (rats) of virus-containing solution was slowly injected into the tissue at each depth. For tracer injections, 50 nl of 5% Fluoro-gold (Fluorochrome, Denver, CO) in 0.9% NaCl or 100 nl of retro-beads (LumaFluor, Durham, NC) diluted 1:1 in 0.9% NaCl was injected at the same set of sites for each injection target. Injections were performed with pulled glass pipettes (beveled and broken to 25–30 μm (outer diameter); Drummond Scientific, Wiretrol II Capillary Microdispenser) backfilled with mineral oil. A fitted plunger was inserted into the pipette and advanced to displace the contents using a hydraulic manipulator (Narashige, MO-10).
[0051] Retraction of the plunger was used to load the pipette with virus. The injection pipette was positioned with a Sutter MP-285 manipulator.
[0052] (Table 1) Coordinates used in this study TIFF0007579301000001.tif53155 * All A / P coordinates are given relative to bregma.
[0053] Example 4 - Library Selection and Evolution The four mutant virus libraries were pooled and injected into either the SNr or cerebellum of adult (6-8 week old) wild-type C57 / Bl6J mice (either sex; Charles River). Three weeks after injection, striatal or hindbrain tissue was removed, DNA extracted, and virions that successfully reached the distant retrograde target tissue were PCR amplified and recloned into the rcAAV packaging plasmid to create a new replication-competent AAV library for the next round of selection. After three rounds of selection, the rescued cap gene was randomly mutagenized by error-prone PCR using the forward and reverse primers 5'-ACG CGG AAG CTT CGA TCA ACT ACG CAG-3' (SEQ ID NO: 79) and 5'-AGA CCA AAG TTC AAC TGA AAC GAA TTA AAC GG-3' (SEQ ID NO: 80), respectively.
[0054] Two additional rounds of in vivo selection were then performed. Individual isolates were sequenced after rounds 4 and 5 to assess the degree of library enrichment (Table 2).
[0055] Table 2. Convergence of peptide insert sequences for variants isolated in rounds 4 and 5 TIFF0007579301000002.tif242139TIFF0007579301000003.tif24286
[0056] Seventeen variants were selected for secondary screening at the end of round 5, and the corresponding cap gene sequences were recloned into rAAV helper plasmids. Individual high-titer preps of the parental wild-type AAV2 and each of the selected 17 mutant variants carrying a CMV-EGFP payload were then prepared by Vector BioLabs, Inc. (Philadelphia, PA). The CMV promoter is typically weak in neurons, so this secondary screening provided a rigorous test of the efficiency of retrograde transport. Individual AAV variants were injected into either the cerebellum or the globus pallidus. After 3 weeks, endogenous, unamplified EGFP fluorescence was visualized in areas expected to be labeled if retrograde transport was efficient. The mutant 5R-Hind6 (SEQ ID NO:43, encoding SEQ ID NO:44) exhibited the strongest retrograde transport in both circuits and was therefore selected for further analysis and designated rAAV2-retro.
[0057] Example 5 - Heparin Binding Assay The heparin affinity of AAV2-retro and wild-type AAV2 was analyzed as previously described (Jang et al., 2011, Mol. Ther., 19:667-75). Briefly, approximately 10 11 The purified genome particles were loaded onto a 1 mL HiTrap heparin column (GE Healthcare Sciences, Piscataway, NJ) pre-equilibrated with 150 mM NaCl and 50 mM Tris, pH 7.5. Elution was then performed by increasing the concentration of NaCl in 50 mM steps to a final concentration of 950 mM, followed by a wash with 1 M NaCl. A small fraction of each eluate was used to infect HEK293T cells, and the percentage of GFP-positive cells was quantified 48 hours postinfection using a Guava EasyCyte 6HT flow cytometer (EMD / Millipore).
[0058] Example 6 - Payloads used in the study For all subsequent experiments, the CMV promoter was replaced with promoters known to be more robust in adult neurons. Cre recombinase and the GCaMP6f calcium sensor were driven by the human synapsin-1 (hSyn1) promoter. All fluorophores were driven by the CAG promoter, and the color-flipping construct was driven by the EF1-α promoter.
[0059] Example 7 - Virus production for quantification of retrograde efficiency The hSyn-Cre payload was packaged using AAV1, AAV2, AAV5, AAV8, AAV9, DJ, and AAV2-retro capsids at the Janelia Viral Shared Resource. All seven viral preparations were processed in parallel and titered prior to in vivo injection. All lots were diluted to the lowest measured titer (1.3E12 GC / ml), and each virus was injected into the right pontine nucleus of three adult Rosa26Lox-STOP-LoxH2B-GFP mice (He et al., 2012, Neuron, 73:35-48).
[0060] Example 8 - Histology Animals were sacrificed 3 weeks after virus injection, at which time the brains were collected and the right hemispheres were sectioned 50 μm sagitally. Sections were mounted in VECTASHIELD Antifade Mounting Medium (Vector Laboratories) containing DAPI and imaged using a 20× objective and FITC and DAPI filters on a PE Pannoramic slide scanner (3D Histech).
[0061] Example 9 - Retrograde transport quantification Images acquired with a panoramic slide scanner were stitched together and then analyzed using custom software written in Matlab (Mathworks) to detect GFP-labeled nuclei throughout the cortex. Regions of interest (ROIs) were manually drawn around the cortex to demarcate areas in the images for automated cell counting. To enhance nuclei detection, the images were then convolved with a "Mexican hat" kernel containing the difference between two Gaussian distributions (26.00 μm variance and 3.25 μm variance). Image noise was reduced using a median filter, followed by basic peak detection.
[0062] Example 10 - Analysis of the generality of retrograde transport Rosa26-LSL-H2B-GFP mice were injected with 25 nl of rAAV2-retro hSyn1-Cre into the dorsal striatum. Three weeks after injection, coronal sections of the brain were imaged using a panoramic scanner to visualize DAPI-stained nuclei and green fluorescence from H2B-GFP-expressing nuclei. The green channel was convolved with the difference of two Gaussian distributions, and peaks were then detected as local maxima on these thresholded images using a custom function written in Matlab. The blue channel of each section was aligned to Nissl images from the Allen Brain Institute's standardized mouse brain atlas using a custom analysis routine written with the aid of the Matlab Image Processing Toolbox. Neurons detected in the aligned sections were then assigned to specific brain regions using annotated regions from the ABI mouse brain atlas.
[0063] It was noted that the finite precision of the reference map, along with individual brain anatomical differences, limited the reliability of this semi-automated process for salient afferent neural inputs.
[0064] Example 11 - Imaging of neuronal population activity in vivo after retrograde delivery of GCaMP6f Seven adult mice were anesthetized with isoflurane (2%) and placed in a stereotaxic frame (Kopf Instruments; Tujunga, CA) on a 37°C heating pad. The scalp and periosteum over the skull were removed, a layer of UV-cured OptiBond adhesive (Kerr; Orange, CA) was applied, and a custom-made headpost (Osborne and Dudman, 2014, PLoS One, 9(2):e89007) was attached with dental cement. AAV2-retro carrying the hSynGCaMP6f payload was injected into the BPN (3.9 mm posterior and 0.4 mm lateral to bregma, 5.8, 5.6, and 5.4 mm deep, 100 nl at each depth) using a Nanoliter 2010 injector (WPI). A cranial window (laser-cut glass, single 170 μm thick pane, 2 mm diameter) was placed over the primary motor cortex (centered 0.7 mm anterior and 1.6 mm lateral to bregma).
[0065] After surgery, injections of ketoprofen (5 mg / kg) and buprenorphine (0.1 mg / kg; Henry Schein Animal Health; Melville, NY) were administered subcutaneously. Mice were allowed to recover for 1 week after surgery and then briefly imaged under a two-photon microscope to assess viral expression. All animals had visually identified GCaMP6f-expressing cells in layer V of the M1 1 week after injection. Animals were then habituated to head fixation in a custom-made apparatus and trained to retrieve food pellets, as previously described (Guo et al., 2014, Nat. Med., 20:130-8).
[0066] GCaMP6f was excited with a Ti:Sapphire laser (Chameleon, Coherent) at 920 nm (typically 20–40 mW at the back aperture) and imaged through a Nikon 16x, 0.8-NA objective. Emission light was passed through a 565 DCXR dichroic filter (Chroma Technology) and an ET525 / 70m-2p filter (Chroma Technology) and detected by a GaAsP photomultiplier tube (10770PB-40, Hamamatsu). Images (512 × 512 pixels) were acquired at approximately 30 Hz on a resonant scanner using ScanImage software.
[0067] Example 12 - CRISPR / Cas9 genome editing The CMV promoter in pAAV-CMV-SaCas9-empty (Slaymaker et al., 2016, Science, 351:84-8) was replaced with hSyn1 to generate pAAV-hSyn1-SaCas9-empty. Oligonucleotides encoding the sgRNA protospacer sequence were custom ordered, phosphorylated, hybridized, and ligated into the BsaI restriction site of pAAV-hSyn1-SaCas9-empty to generate pAAV-hSyn1-SaCas9-tdTomato-1 to -10. The oligonucleotide sequences used were as follows: TIFF0007579301000004.tif143159TIFF0007579301000005.tif78153
[0068] The ability of each oligo to direct genome editing was first assessed in vitro. Neuro2A cells were transfected with 800 ng of pAAV-hSyn1-SaCas9-tdTomato-1–-10, 100 ng of pAAV-FLEX-CAGtdTomato, and 100 ng of pAAV-CAG-EGFP using polyethyleneimine. 72 hours after transfection, cells were harvested, and approximately 70,000 EGFP-positive Neuro2A cells were isolated by fluorescence-activated cell sorting (FACS) using a BD Influx Sorter (BD Biosciences). Genomic DNA was then extracted, and the frequency of tdTomato gene modification was assessed by the Surveyor nuclease assay (Integrated DNA Technologies) as previously described (Cong et al., 2013, Science 339:819-23). sgRNA 7, one of two that appeared to direct two cleavage events within the tdTomato sequence, was packaged into retro-AAV2 and used for in vivo genome editing.
[0069] Then, approximately 100 nl (5 × 10 13AAV2-retro-hSyn1-SaCas9-tdTomato or AAV2retro-hSyn1-SaCas9-empty (vector genome (vg) / ml) was injected into the brain nucleus of Rbp4-Cre × tdTomato mice as described above. Six weeks after injection, brains were harvested and 40-μm-thick coronal sections were cut and stained for HA-tagged Cas9 (anti-HA antibody C29F4 from Cell Signaling, 1:1600 dilution; secondary antibody: donkey anti-mouse Alexa Fluor 488 (1:250; Jackson ImmunoResearch)) and the NeuN neuronal marker (anti-NeuN antibody A60 from Millipore, 1:250 dilution; secondary antibody: donkey anti-rabbit Alexa Fluor 647 (1:500; ThermoFisher, A-31573)). After antibody staining, sections were mounted on slides with VECTASHIELD Antifade Mounting Medium containing DAPI (Vector Laboratories) and visualized using a Zeiss Axio Observer A1 inverted microscope (Zeiss). Quantitation of immunostaining was performed using ImageJ analysis software (NIH).
[0070] Example 13 - Directed evolution of rAAV2-retro To engineer novel rAAVs with enhanced retrograde transport, we designed an in vivo directed evolution approach to enrich for rAAV capsid variants that efficiently transported to the cell bodies of neurons that send long-distance projections to the site of viral injection in the mouse brain (Figure 1A). To maximize the likelihood of recovering variants with desired properties, we used a diverse mixture of previously described libraries of rAAV cap variants (Koerber et al., 2008, Mol. Ther., 16:1703-9; Koerber et al., 2009, Mol. Ther., 17:2088-95; Koerber et al., 2006, Nat. Protocols, 1:701-6; Muller et al., 2003, Nat. Biotechnol., 21:1040-6) as starting material. Viral particles were packaged by linking each variant capsid to the corresponding AAV genome containing the cap gene. The final pool of capsid variants included point mutations, variants with random 7-mer peptide insertions in the region used by AAV2 to bind its coreceptor, heparan sulfate, and random chimeras of capsid gene sequences from seven parental serotypes (Figure 1A). To identify variants with broad retrograde activity, we targeted two distinct populations of projection neurons: striatal GABAergic neurons projecting to the substantia nigra pars reticulata (SNr) and glutamatergic hindbrain neurons projecting to the cerebellar cortex. Three weeks after injection of the entire pool of rAAV variants into the SNr or cerebellum (one injection per animal), striatal or hindbrain tissue, respectively, was harvested, cap sequences were recovered by PCR, and viruses were repackaged (Figure 1B). After two further selection rounds, error-prone PCR was performed to further diversify the library, followed by two final in vivo selection rounds.
[0071] Thirty cap variants were sequenced after the fourth round of evolution, and the majority were derived from the insertion library and contained the exogenous 7-mer peptide between N587 and R588 of the wild-type AAV2 VP1 capsid gene. Interestingly, all of the recovered inserts TIFF0007579301000006.tif7135 or TIFF0007579301000007.tif7135 (bold and italicized residues in the sequence are from the insert); mutations elsewhere in the sequence were also enriched (Table 2). An additional 22 clones were sequenced after the fifth round of evolution, and all sequences in this additional round of evolution AAV2 mutants with the TIFF0007579301000008.tif7154 insert (Table 2) demonstrated a significant degree of further convergence, suggesting that a specific peptide insertion into the heparin-binding loop was largely responsible for retrograde functionality, with potential secondary contributions from other sites.
[0072] A secondary screen of 17 isolated variants carrying various combinations of peptide insertions and point mutations in the capsid sequence was then performed. To apply a high level of stringency, selected variants were packaged with an enhanced green fluorescent protein (EGFP) transgene, which is typically driven by a weak CMV promoter in neurons. Each capsid variant was assessed for its ability to deliver sufficient payload to cell bodies in key afferent regions to allow detection of a non-antibody-amplified EGFP signal 3 weeks after injection. Clones that exhibited the strongest retrograde transport in two independent circuits (cortex to globus pallidus and inferior olive / basal pontine nucleus to cerebellum) in this secondary screen were selected. TIFF0007579301000009.tif7157 was selected for further analysis and designated rAAV2-retro. When two additional promoters more commonly used in rodent in vivo studies were evaluated (CAG—Figure 1B, or human synapsin-1; data not shown), significant retrograde labeling efficiency was observed with this rAAV variant in a range of different circuits in mice and rats (Figure 1B and Figure 7). Swapping the 7-mer insert to one of the other recovered sequences or adding additional point mutations identified in the screen did not result in further increases in retrograde transport.
[0073] Example 14 - Efficient retrograde access to projection neurons Within the descending motor pathway, the corticopontine tract is highly convergent and is known to contribute more than 95% of afferents to the basal pontine nuclei (BPN). This pathway therefore represents a particularly advantageous system for quantifying the efficiency of viral uptake and retrograde transport by axon terminals of projection neurons. Indeed, injection of rAAV2-retro into the BPN resulted in dense labeling of layer V neurons (Figure 2A), consistent with previous tracing studies (Legg et al., 1989, J. Comp. Neurol., 286(4):427-41).
[0074] Next, we compared the efficacy of retrograde transport in the cortico-pontine circuitry for rAAV2-retro versus several commonly used AAV serotypes under identical infection and processing conditions (Figure 2B-D). To ensure quantitative accuracy and eliminate the potential confound of cell-to-cell variability in transgene expression levels, we used AAV to deliver Cre recombinase in Rosa26-Lox-STOP-Lox-H2B-GFP transgenic mice (He et al., 2012, Neuron, 73:35-48). We have shown that even low concentrations of Cre enzyme are sufficient to turn on expression of such a Cre-dependent cassette, and that the precise nuclear localization of the histone fusion reporter allows unambiguous identification of infected cells without confounding neuropil signals.
[0075] Using a semi-automated analysis procedure, we calculated the linear density of infected cortical projection neurons in imaged sagittal sections from mouse brains collected 3 weeks after local viral injection in the BPN (Figure 2C). Minimal cortical GFP expression was observed in rAAV2-infected animals (linear density 0.98 ± 0.20 neurons / mm, mean ± standard error, n = 5; Figure 2B, middle panel). In contrast, and consistent with earlier observations (Figure 2A), a dense layer of GFP-positive layer V projection neurons could be observed throughout the rostrocaudal axis of the cortex in rAAV2-retro-injected animals (linear density 130.11 ± 11.08 neurons / mm, n = 4; Figure 2B, bottom panel). Neither other commonly used AAV serotypes nor canine adenovirus-2 matched the retrograde efficiency of the engineered rAAV2-retro variants (linear densities AAV1: 0.05 ± 0.04, AAV2: 0.98 ± 0.2, AAV5: 2.38 ± 1.24, AAV8: 1.43 ± 1.43, AAV9: 1.98 ± 0.86, DJ: 24.82 ± 14.32, CAV-2: 5.56 ± 4.13, n = 3–5 for each; Figure 2D, Figure 8). Furthermore, the density of cortical projection neurons labeled by rAAV2-retro was comparable to that achieved with Fluoro-Gold (Schmued and Fallon, 1986, Brain Res., 377:147-54), a robust synthetic retrograde tracer (linear density of 81.03 ± 11.08 neurons / mm, n = 3). Thus, rAAV2-retro exhibits up to two orders of magnitude enhancement in retrograde access to corticopontine projection neurons over existing serotypes, rivaling the efficiency of synthetic retrograde tracers.
[0076] Example 15 - Generality of retrograde functionality We next investigated whether the retrograde functionality of rAAV2-retro extended to other circuits by characterizing the extent to which it labeled various afferents to the dorsomedial striatum (DMS), a part of the basal ganglia that receives long-distance inputs from various cortical and subcortical regions. We found that the efficacy of rAAV2-retro-mediated retrograde access to the strongest afferent inputs to the DMS, namely the cortex, thalamus, and amygdala, was comparable to that of fluorescent beads classically used for retrograde tracing (Figure 3A). To provide unbiased estimates of the number of retrogradely labeled neurons in all brain regions known to provide significant long-distance inputs to the DMS, we developed an algorithm to assign any detected fluorescent labeling in imaged mouse brain sections to specific brain regions by aligning sections to the annotated Allen Brain Atlas (Figure 3B-C). Quantitative analysis (Figure 3C) revealed that strong retrograde labeling was found in the vast majority of regions previously reported to send prominent projections to the striatum (Pan et al., 2010, Front Neuroanat., 4:147). With one notable exception, only modest labeling was observed in the substantia nigra pars compacta, despite it being a source of strong dopaminergic input to the DMS (Figure 3C, arrows in cell counts for SNc). Small subsets of projection neuron classes were found to be similarly refractory to retrograde access by rAAV2-retro in several other circuits tested (Table 3; note that all other AAV serotypes tested also failed to label these projection pathways). Despite these exceptions, rAAV2-retro is broadly applicable within the central nervous system.
[0077] Table 3. Efficiency of rAAV2-retro in various circuits. Low efficiency, rather than lack of retrograde transport, in the corticothalamic and cortico-collicular projections is suggested by efficient labeling of projection neurons after local delivery of the Cre-dependent payload to the projection neuron cell bodies. TIFF0007579301000010.tif63170TIFF0007579301000011.tif221166TIFF0007579301000012.tif91168
[0078] Example 16 - Retrograde access to genetically defined neuronal populations We also determined whether the retrograde functionality of rAAV2-retro could be combined with the specificity of Cre transgenic lines to enable the investigation of specific classes of projection neurons. Specifically, experiments were performed to determine whether the combination of rAAV2-retro and Cre transgenic lines could separate two functionally distinct long-range connections that run parallel between two brain regions. Projections from the cerebral cortex to the striatum arise primarily from neurons in layer V, although some neurons in layers II and III also provide striatal input. Inputs to the striatum from different cortical layers constitute separate pathways: neurons in layer V project to the striatal patch compartment, and neurons in layers II and III project to the matrix. The interdigitated nature of the patch compartment and matrix microcompartments makes it difficult to selectively target these pathways for functional investigation using the rAAV2-retro system alone. Therefore, we explored whether the two types of inputs could be separated by combining rAAV2-retro with a transgenic line that expresses Cre recombinase in all layer V neurons (Gerfen et al., 2013, Neuron, 80:1368-83), but not in neurons in layers II and III (Figure 4A).
[0079] To highlight both pathways in the same experiment, we chose a Cre-dependent color-flipping payload that expresses tdTomato in the absence of Cre but flips to drive EGFP expression in Cre-positive cells (Saunders et al., 2012, Front Neural Circuits, 6:47). When rAAV2-retro carrying this payload was injected into the dorsomedial striatum of the layer V-specific Cre driver line Rbp4_KL100 Cre (Gerfen et al., 2013, Neuron, 80:1368-83), only layer V neurons projecting to the striatum expressed EGFP. Furthermore, the corticostriatal pathways in layers II and III were clearly distinguishable by tdTomato expression (Figure 4B). In accordance with the topographical nature of the corticostriatal projection, highly localized injection of the virus into the dorsomedial striatum resulted in labeling of a correspondingly small cortical section. However, layer V and corticostriatal populations in layers II and III were consistently colabeled ( Fig. 4<em>B , bottom panel ), suggesting that two pathways originating from the same cortical region traverse through adjacent matrix and patch microcompartments within the striatum.
[0080] While this experiment highlighted both pathways, choosing a "Cre-on" or "Cre-off" payload would allow selective access to one at the elimination of the other. Therefore, this example highlights the added specificity of circuit interrogation that can be achieved by combining a highly efficient retrovirus with an available Cre (or Flp) driver line.
[0081] Example 17 - Use of rAAV2-retro for circuit interrogation and genetic manipulation The utility of rAAV2-retro for circuit investigation will depend on its ability to mediate high-level expression of genetically encoded indicators and effectors. Its ability to monitor neural activity in defined classes of projection neurons was first assessed through rAAV2-retro-mediated expression of GCaMP6f (Chen et al., 2013, Nature, 499:295-300) (Figure 5A-C). In vivo two-photon Ca 2+ Imaging of dendritic and somatic Ca 2+ A hyperresponsiveness was detected in the primary motor cortex as early as 7 days after viral delivery into the BPN (Fig. 5D). 2+ The temporal profile of the signal reflected the structure of the cued reaching task, with signals in many corticopontine neurons tightly coupled to the "go" cue (Figure 5E-F) (Li et al., 2015, Nature, 519:51-6). Repeated recordings from identified neurons were possible both early in the expression time course across trials within a session (Figure 5E, F) and across many behavioral sessions for more than two months post-infection. Thus, rAAV2-retro confers the ability to express sensors in projection neurons at levels sufficient for imaging, creating many new opportunities for deciphering the contributions of specific projections to circuit computation.
[0082] Finally, we assessed the utility of rAAV2-retro for delivering effectors, such as the CRISPR / Cas9 gene editing system, to projection neurons (Figure 6). Specifically, we packaged Staphylococcus aureus Cas9 (SaCas9 (Slaymaker et al., 2016, Science, 351:84-8)) and a single-guide RNA designed to eliminate tdTomato expression into rAAV2-retro. Delivery of rAAV2-retro-SaCas9-anti-tdTomato to the BPN of animals expressing tdTomato in cortical layer V excitatory neurons resulted in suppression of tdTomato expression in 88.6 ± 0.7% of SaCas9-expressing layer V neurons (Figure 6B, lower panel, and Figure 6C, n = 3). In contrast, delivery of non-targeting SaCas9 did not result in any discernible changes, with only 4.4 ± 3.2% of cells exhibiting a potential reduction in tdTomato expression (Figure 6B, upper panel, and Figure 6C, n = 3). Furthermore, tdTomato expression remained unaffected in layer V neurons, which were difficult to access via pontine injection. The rAAV2-retro system thus enables selective and efficient gene modification in neurons projecting to specific regions of interest.
[0083] Collectively, these observations establish rAAV2-retro as a valid reagent to genetically access projection neurons for functional investigation of neural circuits and, in the long run, for potential therapy.
[0084] Example 18 - Discussion Recombinant adeno-associated viruses can greatly facilitate functional dissection of mammalian neural circuits and hold promise for therapeutic intervention in nervous system disorders. Directed evolution has been used to confer AAV capsids with additional capabilities for efficient retrograde access to projection neurons in many circuits. The newly engineered rAAV2-retro conferred up to two orders of magnitude enhancement in retrograde transport compared with commonly used AAV serotypes, matching the efficacy of synthetic retrograde tracers in many circuits. The level of transgene expression achieved with rAAV2-retro via retrograde access is sufficient for interrogating neural circuit function and for targeted manipulation of neuronal genomes. Thus, by enabling selective monitoring and manipulation of projection neurons connecting various brain regions, rAAV2-retro-based tools are poised to provide insight into how large-scale networks enable brain function and hold promise for therapeutic intervention in diseases characterized by progressive large-scale network dysfunction.
[0085] The significantly increased retrograde access potency achieved by rAAV2-retro compared with its parent serotype, AAV2, may be enabled through insertion-mediated disruption of the native binding site for heparan sulfate and / or through the creation of a new binding surface for the inserted peptide. This variant has reduced heparin affinity (Figure 9), which may reduce viral retention in the extracellular matrix of the synaptic cleft and enhance local vector spread, as observed with AAV1 and AAV6. However, the resulting increased viral spread alone cannot explain the retrograde transport potency, as other inserted 7-mer sequences similarly disrupt heparin binding but do not affect retrograde transport. Furthermore, AAV5 and AAV9 do not bind heparin, yet their retrograde transport efficiency is similar to that of AAV2. In support of an alternative explanation, the peptide inserts selected in the original selections TIFF0007579301000013.tif6144 share the same overall composition, differing simply in the description of conserved motifs. The engineered peptide inserts may support enhanced binding to existing cellular cofactors in the AAV pathway (e.g., the recently identified common AAV receptor) or may create novel interactions with components of the cellular machinery, i.e., cell surface receptors and / or vesicular trafficking or nuclear entry pathways.
[0086] Despite the orders-of-magnitude improvement in retrograde transport that rAAV2-retro confers over existing serotypes, a small set of projection neuron classes appears to be refractory to efficient retrograde infection by this newly evolved rAAV variant (Table 3). It should be noted, however, that other AAV serotypes are unable to similarly label these projection tracts. It remains to be determined in each instance whether the expression levels of critical cellular factors associated with this novel AAV variant in these neurons are indeed extremely low—a conclusion supported, for example, for the corticothalamic and corticocollicular projections by the observation that rAAV2-retro was still able to deliver sufficient Cre recombinase to the cell body to direct high-level expression of locally delivered Cre-dependent payloads (Table 3, highlighted entry)—or whether the factors are completely absent. Additional future capsid modifications to this or other variants may enable enhanced retrograde transduction of these neuronal classes.
[0087] The rAAV2-retro vector system provides an important addition to the genetic toolkit for dissecting neural circuit function, as gaining access to individual classes of projection neurons will be a crucial enabling step in elucidating how local circuit dynamics and large-scale network function are coordinated. Local circuit computations are increasingly thought to depend on the dynamics of the entire neuronal population within a specific local circuit module. How these dynamics map onto different classes of projection neurons, and therefore what information is conveyed to various downstream targets, remains unresolved for most circuits. rAAV2-retro-based vectors, alone or in combination with specific Cre transgenic lines, enable genetic access to specific populations of projection neurons. rAAV2-retro carrying rabies G glycoprotein can then be used to trans-complement newly developed non-toxic conditional rabies vectors for access to presynaptic microcircuits that affect specific classes of projection neurons. The resulting ability to selectively monitor and manipulate the activity of individual projection neuron classes and their local microcircuits should provide insight into how projection neurons translate local circuit dynamics for their respective large-scale networks.
[0088] rAAV2-retro also holds promise for therapeutic intervention, with several potential applications. For example, in situations where pathology affects large amounts of neural tissue, such as Alzheimer's disease or lysosomal storage diseases, multiple injections pose safety risks and may be insufficient to achieve the required level of transduction. However, a small number of injections at strategic locations can enable vector distribution across large volumes (e.g., cortico-pontine tracts from points of convergence in BPN) or difficult-to-access tissues (e.g., spinal motor neurons from muscle). Furthermore, large-scale functional networks are implicated in the spread of many neurodegenerative disorders from their spatially localized onset. A prominent emerging idea posits that the deposition of abnormal protein assemblies in vulnerable neuronal populations triggers a pathological cascade of aberrant neuronal activity within large-scale functional networks and their collapse, ultimately resulting in neurological dysfunction. Interestingly, affected neural networks appear to be able to transiently overcome abnormal dynamics early in the course of the disease, as patients with many neurodegenerative diseases often experience periods of dramatic improvement. Therefore, early intervention aimed at slowing the spread of aggregates from the cortical origin of the lesion may be sufficient to stabilize or even restore cognitive function. From this perspective, subcortically projecting neurons in mesocortical regions, where pathological protein aggregates first appear, constitute attractive intervention targets in both Alzheimer's and Parkinson's disorders. For example, accessing these projecting neurons with rAAV2retro-based tools designed to introduce mutations that can halt further aggregation in cis or to deliver chaperones that can mask aggregates, has the potential to slow the progression of the most debilitating dementia symptoms. Evaluation of the efficacy and long-term safety of rAAV2retro reagents in nonhuman primates will pave the way for eventual consideration of these and other gene therapy approaches.
[0089] While the subject methods and compositions have been described herein along with numerous different aspects, the foregoing description of the various aspects is intended to be illustrative of the subject methods and compositions, and not to limit their scope. Other aspects, advantages, and modifications are within the scope of the following claims.
[0090] Disclosed are methods and compositions that can be used for, can be used in conjunction with, can be used in preparation for, or are the product of the disclosed methods and compositions. These and other materials are disclosed herein, and it is understood that combinations, subsets, interactions, groups, etc. of these methods and compositions are disclosed. That is, although specific reference to various individual and collective combinations and permutations of each of these compositions and methods may not be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular composition or particular method in question is disclosed and discussed, and numerous compositions or methods are discussed, each and every combination and permutation of the compositions and methods is specifically contemplated unless specifically indicated to the contrary. Likewise, any subset or combination of these is also specifically contemplated and disclosed.
Claims
1. An adeno-associated virus 2 (AAV2) VP1 capsid protein comprising the amino acid sequence of SEQ ID NO: 82, 85, or 86, wherein the amino acid sequence is inserted between amino acids N587 and R588 of the AAV2 VP1 capsid protein, numbered corresponding to SEQ ID NO: 109, and wherein the AAV2 VP1 capsid protein does not contain an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 32, 38, 44, 48, 60, 72, 74, and 76.
2. The AAV2 VP1 capsid protein of claim 1, further comprising a V708I amino acid substitution.
3. 3. The AAV2 VP1 capsid protein of claim 1 or 2, further comprising one or more of the following amino acid substitutions: E12V, P29A, H38L, E36G, D41G, L59P, E67A, D69E, K105E, K137E, E147A, G163D, V182E, V182I, Q186R, S207G, N214D, N227D, M235L, F284Y, N335K, N382D, N408S, S423N, S492P, S492Y, N496D, N496Y, N587S, D594N, R585G, T567A, or S662C.
4. 1. An AAV2 VP1 capsid protein comprising the amino acid sequence of the sequence LAX 1X 2DX 3TKX 4A (SEQ ID NO: 107), (a) X 1 is D, I, N, or Q, X 2 is Q, S, or P, X 3 is Y, Q, or A, and X 4 is T, H, or N; (b) the amino acid sequence is inserted between amino acids N587 and R588 of the AAV2 VP1 capsid protein, numbered according to SEQ ID NO: 109; (c) the AAV2 VP1 capsid protein comprises an N382D and a V708I amino acid substitution; and (d) the AAV2 VP1 capsid protein does not contain the amino acid sequence of SEQ ID NO: 30 or 44; AAV2 VP1 capsid protein.
5. The AAV2 VP1 capsid protein of claim 4, wherein the amino acid sequence inserted into the capsid protein comprises the sequence LADQDYTKTA (SEQ ID NO:85).
6. A viral particle comprising a viral capsid protein according to any one of claims 1 to 5.
7. The viral particle of claim 6, which exhibits an enhanced preference for retrograde movement compared to wild-type viral particles.
8. The viral particle of claim 6 , which possesses retrograde transport ability.
9. The viral particle of claim 6 , further comprising a payload.
10. The viral particle of claim 9 , wherein the payload is a protein-encoding gene or an inhibitory RNA nucleic acid.
11. The viral particle of claim 10, wherein the payload is an inhibitory RNA nucleic acid selected from the group consisting of an antisense oligonucleotide, an siRNA, and an RNAi.
12. The viral particle of claim 10, wherein the payload is a nucleic acid encoding an optical reporter.
13. The viral particle of claim 10, wherein the payload is a nucleic acid encoding a viral protein.
14. The viral particle of claim 10, wherein the payload is a nucleic acid encoding a therapeutic protein.
15. The viral particle of claim 9 , wherein the payload comprises a nucleic acid comprising a promoter sequence operably linked to a protein-encoding gene.
16. The viral particle of claim 15 , wherein the promoter is a neuron-specific promoter.
17. The viral particle of claim 15, wherein the promoter is selected from the group consisting of synapsin-1, CMV, GFAP, CAG, CaMKII, MBP, EF1α, TRE, and mDlx promoters.
18. 10. An in vitro or ex vivo method of delivering a payload to one or more neurons comprising contacting one or more neurons with a viral particle as described in claim 6, wherein the viral particle contains a payload packaged therein.
19. A pharmaceutical comprising the viral particle of claim 6 for treating a neurodegenerative disorder, wherein the viral particle contacts one or more neurons, and the viral particle comprises a payload packaged therein.
20. A host cell transduced with or infected with a virus comprising a nucleic acid molecule encoding the AAV2 VP1 capsid protein of any one of claims 1 to 5.
Citation Information
Patent Citations
JPP7094277B
Compositions and methods for targeting of viral vectors
WO2006119150A2
Optimized AAV-vectors for high transduction rates in dendritic cells
WO2013174760A1
